Health ❯ Healthcare ❯ Clinical Trials

Oncology

Multiple Myeloma Immunotherapy Head and Neck Cancer Melanoma Precision Medicine Breast Cancer Follicular Lymphoma Patient Outcomes Chronic Myeloid Leukemia Enzalutamide Therapy Radiopharmaceuticals Small Lymphocytic Lymphoma Neurofibromatosis Chemotherapy Diffuse Large B-Cell Lymphoma Autoimmunity Lung Cancer Research Lymphoma Chronic Lymphocytic Leukaemia Gastroesophageal Cancer Hepatocellular Carcinoma Renal Cell Carcinoma Chronic Lymphocytic Leukemia Myeloproliferative Neoplasms Prostate Cancer Phase 3 Trials Colorectal Cancer Metastatic Uveal Melanoma B-cell Malignancies Myelofibrosis Gastrointestinal Cancer

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

The results position darovasertib plus crizotinib for an FDA submission in the second half of 2026.

Trials Show Fecal Transplants Enhance Cancer Immunotherapy, Including Longer PFS in Randomized Kidney Study

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Global Trial Finds Many Post-Mastectomy Patients Can Skip Chest-Wall Radiotherapy

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Bristol Myers’ Iberdomide Combo Hits MRD Goal in Phase 3 Myeloma Study

Replimune Reports No Defined Accelerated-Approval Path After FDA Type A Meeting on RP1 for Melanoma

Modified Herpes Virus Plus Nivolumab Induces Tumor Regression in Advanced Melanoma

PROX1 gene drives aggressive, treatment-resistant prostate cancer